COVID-19 mRNA Vaccines and Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
The Coronavirus Disease 2019 (COVID-19) messenger RNA (mRNA) vaccines, BNT162b2 and mRNA-1273, manufactured by Pfizer-BioNTech and Moderna, respectively, received the United States Food and Drug Administration (FDA) emergency use authorization in December 2020 and have since been widely administered. Recognizing the increased mortality risk from COVID-19 in cancer patients1, the major cancer scientific societies such as the American Society of Clinical Oncology (ASCO)2, European Society for Medical Oncology (ESMO)3, and National Comprehensive Cancer Network (NCCN)4 generally recommend COVID-19 vaccination in cancer patient...
Source: European Journal of Cancer - July 27, 2021 Category: Cancer & Oncology Authors: Yu-Wei Chen, Matthew D. Tucker, Kathryn E. Beckermann, Wade T. Iams, Brian I. Rini, Douglas B. Johnson Tags: Letter to the Editor Source Type: research

Erratum to “α4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients” [Eur J Canc 50 (2014) 840–851]
The publisher regrets that panel D of Figure  5 was mistakenly given as a duplicate of Fig 3A in the published article. The correct image for Fig 5D is given below. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 21, 2021 Category: Cancer & Oncology Authors: Jianye Liu, Muyan Cai, Jiewei Chen, Yiji Liao, Shijuan Mai, Yonghong Li, Xiaoxia Huang, Yanhui Liu, Jiaxing Zhang, Hsiangfu Kung, Yixin Zeng, Fangjian Zhou, Dan Xie Tags: Erratum Source Type: research

Refusal of anti-COVID-19 vaccination in cancer patients: is there a difference between the sexes?
Cancer patients have a higher than average risk of death from COVID-19 (1), and the positive effects of vaccination have been confirmed (2). Nevertheless, a study by Di Noia et al. published in the European Journal of Cancer has reported a high rate of refusal of anti-COVID-19 vaccination in a cohort of 914 Italian cancer patients (3). We performed an analogous, but qualitative study at Foch Hospital, with the aim of identifying the reasons for which patients treated by chemotherapy or immunotherapy at the day hospital refuse anti-COVID-19 vaccination, even after receiving information on the subject during a consultation. ...
Source: European Journal of Cancer - July 20, 2021 Category: Cancer & Oncology Authors: Henri-Corto Stoekl é, Sakina Sekkate, Elisabeth Angellier, Christian Hervé, Philippe Beuzeboc Tags: Letter to the Editor Source Type: research

Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial
Radical (chemo)radiotherapy offers potentially curative treatment for patients with locally advanced laryngeal or hypopharyngeal cancer. We aimed to show that dose-escalated intensity-modulated radiotherapy (DE-IMRT) improved locoregional control. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 11, 2021 Category: Cancer & Oncology Authors: Christopher M. Nutting, Clare L. Griffin, Paul Sanghera, Bernadette Foran, Matthew Beasley, David Bernstein, Vivian Cosgrove, Shelia Fisher, Catherine M. West, Amen Sibtain, Nachi Palaniappan, Teresa Guerrero Urbano, Mehmet Sen, Win Soe, Mohammed Rizwanul Tags: Clinical Trial Source Type: research

Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers
Dabrafenib plus trametinib has demonstrated clinical benefit across multiple BRAF-mutant tumours, leading to approval for resected stage III and metastatic melanoma, non –small-cell lung cancer (NSCLC) and anaplastic thyroid cancer. Pyrexia is a common adverse event in patients treated with dabrafenib plus trametinib. Here, we characterise the incidence, patterns and management of pyrexia in patients receiving dabrafenib plus trametinib in clinical trials. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 2, 2021 Category: Cancer & Oncology Authors: Dirk Schadendorf, Caroline Robert, Reinhard Dummer, Keith T. Flaherty, Hussein A. Tawbi, Alexander M. Menzies, Hiya Banerjee, Mike Lau, Georgina V. Long Tags: Original Research Source Type: research

Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti –PD-1 therapy
Combination immunotherapy with nivolumab and ipilimumab has a high initial response rate in advanced melanoma; however, up to 55% of patients later progress. The efficacy and safety of ipilimumab re-induction in the setting of acquired resistance (AR) to combination immunotherapy is unknown. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 29, 2021 Category: Cancer & Oncology Authors: Adriana Hepner, Victoria G. Atkinson, James Larkin, Rebecca A. Burrell, Matteo S. Carlino, Douglas B. Johnson, Lisa Zimmer, Katy K. Tsai, Oliver Klein, Serigne N. Lo, Andrew Haydon, Prachi Bhave, Megan Lyle, Lalit Pallan, Ines Pires da Silva, Camille Gera Tags: Original Research Source Type: research

Preservation of quality of life in patients with human epidermal growth factor receptor 2 –positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)
In HER2CLIMB, tucatinib significantly improved progression-free and overall survival in patients with human epidermal growth factor receptor 2 –positive (HER2+) metastatic breast cancer. We evaluated the impact of tucatinib on health-related quality of life (HR-QoL) in HER2CLIMB. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 29, 2021 Category: Cancer & Oncology Authors: Volkmar Mueller, Andrew Wardley, Elisavet Paplomata, Erika Hamilton, Amelia Zelnak, Louis Fehrenbacher, Erik Jakobsen, Elsa Curtit, Frances Boyle, Eva Harder Brix, Andrew Brenner, Laurence Crouzet, Cristiano Ferrario, Montserrat Mu ñoz-Mateu, Hendrik-Tob Tags: Original Research Source Type: research

COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a worldwide survey (The INTENSIVE study)
Specific data regarding COVID-19 in patients with neuroendocrine neoplasms (NEN) are lacking. This aim of this study is to describe the characteristics of NEN patients who tested SARS-CoV-2 positive. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 29, 2021 Category: Cancer & Oncology Authors: Nicola Fazio, Lorenzo Gervaso, Thorvadur R. Halfdanarson, Anna La Salvia, Johannes Hofland, Jorge Hernando, Mohamad B. Sonbol, Rocio Garcia-Carbonero, Jaume Capdevila, Wouter W. de Herder, Anna Koumarianou, Gregory Kaltsas, Maura Rossi, Simona Grozinsky-G Tags: Original Research Source Type: research

Informative censoring of surrogate end-point data in phase 3 oncology trials
Kaplan –Meier (K-M) analysis, the cornerstone of cancer clinical trial interpretation, assumes that censored patients are no more or less likely to experience an event than those followed. We sought to investigate the patterns of censoring in surrogate end-points of oncology randomised controlled trials (RCTs) and examine the relationship between censoring in practice-changing treatments that failed to demonstrate survival gain. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 26, 2021 Category: Cancer & Oncology Authors: Shai Gilboa, Yarden Pras, Aviv Mataraso, David Bomze, Gal Markel, Tomer Meirson Tags: Original Research Source Type: research

Utility of the CPS  + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
Pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) is associated with superior survival. This association is strongest in triple-negative breast cancer (TNBC). The CPS  + EG system, based on pre-treatment clinical (CS) and post-treatment pathological stage (PS), oestrogen-receptor status (E) and grade (G), leads to a refined estimate of prognosis after NACT in all-comers and hormone receptor–positive/human epidermal growth factor receptor 2 (HER2)-negative bre ast cancer. Here, we investigate if CPS + EG scoring provides a superior estimate of prognosis in TNBC to select pa...
Source: European Journal of Cancer - June 26, 2021 Category: Cancer & Oncology Authors: Frederik Marm é, Christine Solbach, Laura Michel, Andreas Schneeweiss, Jens-Uwe Blohmer, Jens Huober, Peter A. Fasching, Christian Jackisch, Valentina Nekljudova, Theresa Link, Kerstin Rhiem, Julia Rey, Carsten Denkert, Claus Hanusch, Hans Tesch, Bianca Tags: Original Research Source Type: research

Covid-19 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up - a monocenter study
The Covid-19 pandemic has changed the lives of people around the world. Fortunately, sufficient vaccines are now available. Local reactions with ipsilateral lymphadenopathy are among the most common side effects. We investigated the impact of lymphadenopathy after Covid-19 vaccination on the value of ultrasound in tumor patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 26, 2021 Category: Cancer & Oncology Authors: J.-M. Placke, H. Reis, E. Hadaschik, A. Roesch, D. Schadendorf, I. Stoffels, J. Klode Tags: Original Research Source Type: research

Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Combination ipilimumab and nivolumab is approved for several malignancies. Toxicity most often occurs 6 –10 weeks into treatment. Whether very early toxicity is harder to manage or influences efficacy is unknown. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 25, 2021 Category: Cancer & Oncology Authors: Helen Dearden, Lewis Au, Daniel Y. Wang, Lisa Zimmer, Zeynep Eroglu, Jessica L. Smith, Marcello Cuvietto, Chloe Khoo, Victoria Atkinson, Serigne Lo, Georgina V. Long, Shahneen Sandhu, Paolo A. Ascierto, Matteo S. Carlino, Douglas B. Johnson, James Larkin, Tags: Original Research Source Type: research

Clinical decision support algorithm based on machine learning to assess the clinical response to anti –programmed death-1 therapy in patients with non–small-cell lung cancer
Anti –programmed death (PD)-1 therapy confers sustainable clinical benefits for patients with non–small-cell lung cancer (NSCLC), but only some patients respond to the treatment. Various clinical characteristics, including the PD-ligand 1 (PD-L1) level, are related to the anti–PD-1 response; howeve r, none of these can independently serve as predictive biomarkers. Herein, we established a machine learning (ML)–based clinical decision support algorithm to predict the anti–PD-1 response by comprehensively combining the clinical information. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 25, 2021 Category: Cancer & Oncology Authors: Beung-Chul Ahn, Jea-Woo So, Chun-Bong Synn, Tae Hyung Kim, Jae Hwan Kim, Yeongseon Byeon, Young Seob Kim, Seong Gu Heo, San-Duk Yang, Mi Ran Yun, Sangbin Lim, Su-Jin Choi, Wongeun Lee, Dong Kwon Kim, Eun Ji Lee, Seul Lee, Doo-Jae Lee, Chang Gon Kim, Sun M Tags: Original Research Source Type: research

Erratum to ‘Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis’ [Eur J Cancer 149 (2021) 134–152]
The publisher regrets that errors were made regarding the named trial PRIMA in section 4.4. ‘Results based on mutational status’. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 25, 2021 Category: Cancer & Oncology Authors: Francesco Schettini, Fabiola Giudici, Ottavia Bernocchi, Marianna Sirico, Silvia P. Corona, Mario Giuliano, Mariavittoria Locci, Ida Paris, Giovanni Scambia, Sabino De Placido, Pasquale Rescigno, Aleix Prat, Giuseppe Curigliano, Daniele Generali Tags: Erratum Source Type: research

BNT162b2 mRNA Covid-19 Vaccine in AYA with cancer: a monocentric experience
COVID-19 infection in pediatric cancer patients is severe or critical in 20% of the patients. It can therefore directly affect pediatric cancer patients and/or their care. We aimed at evaluating the safety and efficacy of BNT162b2 mRNA Covid-19 vaccine in AYA with solid tumor. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 23, 2021 Category: Cancer & Oncology Authors: Gabriel Revon-Riviere, Laetitia Ninove, Victoria Min, Ang élique Rome, Carole Coze, Arnauld Verschuur, Xavier de Lamballerie, Nicolas André Tags: Original Research Source Type: research

Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy
Thymic carcinoma (TC) is a rare aggressive tumour occurring in adults characterised by one of the lowest tumor mutational burdens (TMB). Microsatellite instability (MSI) is a mutational signature, caused by defects in the DNA MisMatch Repair (MMR) system, that predicts benefit from immunotherapy  and causes high TMB. Fragmentary and unstructured evidence of these conditions co-occurring are reported in literature. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 20, 2021 Category: Cancer & Oncology Authors: M. Repetto, F. Conforti, S. Pirola, M. Calvello, L. Pala, B. Bonanni, C. Catania, G. Curigliano, T. De Pas Tags: Original Research Source Type: research

Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial
The Cher-LOB randomised phase II study showed that the combination of lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. Here, we report the post hoc survival analysis as per treatment arm, pCR and biomarkers. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 19, 2021 Category: Cancer & Oncology Authors: Valentina Guarneri, Maria V. Dieci, Gaia Griguolo, Federica Miglietta, Fabio Girardi, Giancarlo Bisagni, Daniele G. Generali, Katia Cagossi, Samanta Sarti, Antonio Frassoldati, Lorenzo Gianni, Luigi Cavanna, Graziella Pinotti, Antonino Musolino, Federico Tags: Original Research Source Type: research

Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial
This is the first randomised study to evaluate toxicity and survival outcomes of two neoadjuvant chemoradiotherapy (CRT) regimens for patients with localised oesophageal adenocarcinoma (OAC) or gastro-oesophageal junction (GOJ) adenocarcinoma. The initial results showed comparable toxicity between regimens and pathological complete response (pCR) rate favouring CarPacRT. Herein, we report survival, progression patterns, and long-term toxicity after a median follow-up of 40.7 months. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 19, 2021 Category: Cancer & Oncology Authors: Somnath Mukherjee, Christopher Hurt, Ganesh Radhakrishna, Sarah Gwynne, Andrew Bateman, Simon Gollins, Maria A. Hawkins, Joanne Canham, Heike I. Grabsch, Stephen Falk, Ricky A. Sharma, Ruby Ray, Rajarshi Roy, Catrin Cox, Nick Maynard, Lisette Nixon, David Tags: Original Research Source Type: research

Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies
This phase 1 study evaluated safety, pharmacokinetics (PK), maximum tolerated dose (MTD), and antitumour activity of regorafenib in paediatric patients with solid tumours. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 19, 2021 Category: Cancer & Oncology Authors: Birgit Geoerger, Bruce Morland, Irene Jim énez, Didier Frappaz, Andrew D.J. Pearson, Gilles Vassal, Patricia Maeda, Jasmine Kincaide, Udo Mueller, Sarah Schlief, Michael Teufel, Bart A. Ploeger, Adriaan Cleton, Andrea C. Agostinho, Lynley V. Marshall Tags: Original Research Source Type: research

Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments
OBP-301 (Telomelysin) is an attenuated type-5 adenovirus that contains the human telomerase reverse transcriptase  promoter to regulate viral replication. OBP-301 sensitises human cancer cells to ionising radiation by inhibiting DNA repair, and radiation enhances coxsackievirus and adenovirus receptor–mediated OBP-301 infection on the contrary. We assessed OBP-301 with radiotherapy in oesophageal cancer pat ients unfit for standard chemoradiation treatments. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 18, 2021 Category: Cancer & Oncology Authors: Yasuhiro Shirakawa, Hiroshi Tazawa, Shunsuke Tanabe, Nobuhiko Kanaya, Kazuhiro Noma, Takeshi Koujima, Hajime Kashima, Takuya Kato, Shinji Kuroda, Satoru Kikuchi, Shunsuke Kagawa, Kuniaki Katsui, Susumu Kanazawa, Yasuo Urata, Toshiyoshi Fujiwara Tags: Original Research Source Type: research

Could controlling occult cytomegalovirus reactivation with prophylactic valganciclovir prevent immune checkpoint blockade –Related complications?
A recent article in Nature Communications makes provocative claims about the immunopathogenesis of hepatitis in a subset of patients receiving combined immune checkpoint blockade [1]. The central tenet of this report is cytomegalovirus (CMV)-specific memory T cell responses are primarily responsible for liver inflammation in certain patients with advanced melanoma receiving αPD-1 and αCTLA-4 therapy. This conclusion stems from the discovery that elevated CD4+ effector memory T cell (TEM) frequency in the blood is strongly associated with CMV serostatus and hepatitis risk. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 18, 2021 Category: Cancer & Oncology Authors: Axel Hauschild Tags: Letter to the Editor Source Type: research

NeoRAS wild-type in metastatic colorectal cancer: Myth or truth? —Case series and review of the literature
Upfront KRAS and NRAS gene testing ( ‘RAS’) is the standard of care for metastatic colorectal cancer (mCRC), to guide first-line treatment. The presence of RAS mutation (MT) is a negative predictor for the efficacy of anti-EGFR antibodies and the use of cetuximab and panitumumab is restricted to RAS wild-type (WT) mCRC. Conversion from RAS WT to RAS MT mCRC after treatment with anti-EGFR antibodies is a known and well-described acquired resistance mechanism. The by far less frequent ‘NeoRAS wild-type’ phenomenon (reversion from RAS MT to RAS WT) has recently drawn attention. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 18, 2021 Category: Cancer & Oncology Authors: Hiroki Osumi, Loredana Vecchione, Ulrich Keilholz, Claudia Vollbrecht, Annabel H.S. Alig, Jobst C. von Einem, Arndt Stahler, Jana K. Striefler, Annika Kurreck, Andreas Kind, Dominik P. Modest, Sebastian Stintzing, Ivan Jelas Tags: Original Research Source Type: research

A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southeast Asia, particularly Southern China. The classical non-keratinising cell type is almost unanimously associated with latent Epstein –Barr virus (EBV) infection. Circulating plasma EBV DNA can be a useful biomarker in various clinical aspects, but comprehensive recommendations and international guidelines are still lacking. We conducted a systematic review of all original articles on the clinical application of plasma EBV DNA f or NPC; we further evaluated its strengths and limitations for consideration as standard recommendations. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 18, 2021 Category: Cancer & Oncology Authors: Anne W.M. Lee, Victor H.F. Lee, Wai-Tong Ng, Primo ž Strojan, Nabil F. Saba, Alessandra Rinaldo, Stefan M. Willems, Juan P. Rodrigo, Arlene A. Forastiere, Alfio Ferlito Tags: Review Source Type: research

Successful rechallenge with avelumab in Merkel cell carcinoma
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer associated with poor prognosis. Patients are often diagnosed at a metastatic stage and the treatment which consisted until recently in polychemotherapy was associated with relatively high objective response rates (ORR ranging from 20 to 61%), but very few complete responses (CR) and short duration response (1.3 –3.3 months) [1,2]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 18, 2021 Category: Cancer & Oncology Authors: Mathilde Amiot, Florence Brunet Possenti, C éleste Lebbé, Barouyr Baroudjian Tags: Letter to the Editor Source Type: research

The European multistakeholder PanCareFollowUp project: novel, person-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for cancer survivors and caregivers
The majority of childhood cancer survivors are at risk of treatment-related adverse health outcomes. Survivorship care to mitigate these late effects is endorsed, but it is not available for many adult survivors of childhood cancer in Europe. The PanCareFollowUp project was initiated to improve their health and quality of life (QoL) by facilitating person-centred survivorship care. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 18, 2021 Category: Cancer & Oncology Authors: Rebecca J. van Kalsbeek, Helena J.H. van der Pal, Lars Hjorth, Jeanette F. Winther, Gisela Michel, Riccardo Haupt, Anne Uyttebroeck, Kylie O'Brien, Katerina Kepakova, Cecilia Follin, Monica Muraca, Tomas Kepak, Vera Araujo-Soares, Edit Bardi, Anne Blondee Tags: Original Research Source Type: research

Re: Comments on ‘High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non–small cell lung cancer patients’
We thank Dr Akio Hara and Prof. Takashi Yoshioka and colleagues for their interest and comments on our study investigating the association between high-intensity statins and clinical outcome in malignant pleural mesothelioma (MPM) and advanced non –small cell lung cancer (aNSCLC) patients treated with programmed cell death protein 1 (PD-1) inhibitors [1]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 18, 2021 Category: Cancer & Oncology Authors: Luca Cantini, Federica Pecci, Floris Dammeijer, Joachim G.J.V. Aerts, Rossana Berardi Tags: Letter to the Editor Source Type: research

Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials
Immune checkpoint inhibitors (ICIs) are revolutionary anticancer drugs approved in an expanding variety of cancer types [1]. ICIs restore the activity of the immune system and primarily of T cells to destroy neoplastic cells [1]. Currently, approved ICIs are monoclonal antibodies blocking cytotoxic T-lymphocyte –associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1), which are immune checkpoint brakes expressed on T cells [1]. ICIs also include anti–PD-L1 (PD1 ligand located on cancer cells) normally interacting with PD1 to tone down T cells [1]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 18, 2021 Category: Cancer & Oncology Authors: Joe-Elie Salem, Stephane Ederhy, Agn ès Dechartres Tags: Letter to the Editor Source Type: research

Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors
We read with great interest the article by Kramer et  al. [1] on the haematological adverse effects associated with immune checkpoint inhibitors (ICIs). The authors have extensively discussed several rare but clinically significant hematological adverse effects that may also prove to be fatal in some cases. The adverse effect that drew our attention, in particular, is haemophagocytic lymphohistiocytosis (HLH). HLH is a potentially fatal clinical syndrome that results from a severe, uncontrolled hyperinflammatory state, which may be triggered by several causes such as infection, malignancy, drugs and so on [2]. (Source...
Source: European Journal of Cancer - June 18, 2021 Category: Cancer & Oncology Authors: Udhayvir S. Grewal, Sahith R. Thotamgari, Parth R. Shah, Jasmeen K. Uppal, Shiva J. Gaddam Tags: Letter to the Editor Source Type: research

Response to letter entitled: ‘Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors’
Checkpoint inhibitor –induced haemophagocytic histiocytosis (HLH) is an important side-effect with a challenging therapy and high mortality rate. Thus, we agree that it is critical to raise awareness to the condition, which allows early detection and treatment. It is also essential to gather data on these events to es tablish best practice. Case reports are an important tool to identify signals for further investigation of such rare events as has been the case for cardiomyositis [1], which triggered an US Food and Drug Administration (FDA) initiative. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 18, 2021 Category: Cancer & Oncology Authors: Lucie Heinzerling, Paul La Ros ée, Ralf Gutzmer, Rafaela Kramer, Brigitte Keller-Stanislawski, Sarah Zierold, Dirk Mentzer Tags: Letter to the Editor Source Type: research

Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer
A higher risk of death from coronavirus disease 19 (COVID-19) has been shown for patients with solid cancers (SC) or hematologic cancers (HM). Thanks to the accelerated development of anti-SARS-SoV-2 vaccines in less than a year since the start of the global pandemic, patients with cancer were quickly prioritized in early 2021 for vaccination, however dependent on the very unequal availability at the global level. Impaired immunogenicity of SARS-CoV-2 mRNA vaccines in immunocompromised patients was rapidly reported as early as April 2021, although the vaccination fortunately appears to be generally effective without increa...
Source: European Journal of Cancer - June 18, 2021 Category: Cancer & Oncology Authors: J érôme Barrière, Daniel Re, Frédéric Peyrade, Michel Carles Tags: Current Perspective Source Type: research

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
The aim of the study was to assess patient preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in patients with HER2-positive early breast cancer in PHranceSCa (NCT03674112). (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 16, 2021 Category: Cancer & Oncology Authors: Joyce O'Shaughnessy, Susana Sousa, Josefina Cruz, Lesley Fallowfield, P äivi Auvinen, Catarina Pulido, Ana Cvetanovic, Sharon Wilks, Leonor Ribeiro, Mauricio Burotto, Dirk Klingbiel, Dimitri Messeri, Ari Alexandrou, Peter Trask, Judy Fredriksson, Zuzana Tags: Original Research Source Type: research

Integration of quantitative imaging biomarkers in clinical trials for MR-guided radiotherapy: Conceptual guidance for multicentre studies from the MR-Linac Consortium Imaging Biomarker Working Group
Quantitative imaging biomarkers (QIBs) derived from MRI techniques have the potential to be used for the personalised treatment of cancer patients. However, large-scale data are missing to validate their added value in clinical practice. Integrated MRI-guided radiotherapy (MRIgRT) systems, such as hybrid MRI-linear accelerators, have the unique advantage that MR images can be acquired during every treatment session. This means that high-frequency imaging of QIBs becomes feasible with reduced patient burden, logistical challenges, and costs compared to extra scan sessions. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 15, 2021 Category: Cancer & Oncology Authors: Petra J. van Houdt, Hina Saeed, Daniela Thorwarth, Clifton D. Fuller, William A. Hall, Brigid A. McDonald, Amita Shukla-Dave, Ernst S. Kooreman, Marielle E.P. Philippens, Astrid L.H.M.W. van Lier, Rick Keesman, Faisal Mahmood, Catherine Coolens, Teodor St Tags: Current Perspective Source Type: research

Wilms tumour surveillance in at-risk children: Literature review and recommendations from the SIOP-Europe Host Genome Working Group and SIOP Renal Tumour Study Group
Since previous consensus-based Wilms tumour (WT) surveillance guidelines were published, novel genes and syndromes associated with WT risk have been identified, and diagnostic molecular tests for previously known syndromes have improved. In view of this, the International Society of Pediatric Oncology (SIOP)-Europe Host Genome Working Group and SIOP Renal Tumour Study Group hereby present updated WT surveillance guidelines after an extensive literature review and international consensus meetings. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 13, 2021 Category: Cancer & Oncology Authors: Janna A. Hol, Rosalyn Jewell, Tanzina Chowdhury, Catriona Duncan, Kayo Nakata, Takaharu Oue, Marion Gauthier-Villars, Annemieke S. Littooij, Yasuhiko Kaneko, Norbert Graf, Franck Bourdeaut, Marry M. van den Heuvel-Eibrink, Kathy Pritchard-Jones, Eamonn R. Tags: Review Source Type: research

Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies
Although previously the mainstay of treatment, the role of surgery in the management of patients with oligometastatic stage IV melanoma has changed with the advent of effective systemic therapies (most notably immunotherapy). Contemporary treatment options for patients with asymptomatic solitary or oligo-metastases include upfront surgery followed by adjuvant immunotherapy or upfront immunotherapy with salvage surgery as required. For suspected solitary or oligo-metastases, surgery serves both diagnostic and therapeutic purposes. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 12, 2021 Category: Cancer & Oncology Authors: Sydney Ch'ng, Semra Uyulmaz, Matteo S. Carlino, Thomas E. Pennington, Kerwin F. Shannon, Michael Rtshiladze, Jonathan R. Stretch, Omgo E. Nieweg, Alexander H.R. Varey, Edward Hsiao, Rony Kapoor, Ines Pires da Silva, Serigne N. Lo, Andrew J. Spillane, Rich Tags: Current Perspective Source Type: research

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in F édération Francophone de Cancérologie Digestive (FFCD) trials
Few studies have explored the association between baseline characteristics and the occurrence of early toxicities in patients treated with first-line chemotherapy for metastatic colorectal cancer (mCRC). (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 12, 2021 Category: Cancer & Oncology Authors: Cl émence Breton, Thomas Aparicio, Karine Le Malicot, Michel Ducreux, Thierry Lecomte, Jean-Baptiste Bachet, Julien Taieb, Jean-Louis Legoux, Aimery De Gramont, Jaafar Bennouna, Olivier Bouché, Olayide Boussari, Sylvain Manfredi, Jean-Marc Gornet Tags: Original Research Source Type: research

Antibiotic-induced disruption of the microbiome exacerbates chemotherapy-induced diarrhoea and can be mitigated with autologous faecal microbiota transplantation
Chemotherapy is well documented to disrupt the gut microbiome, leading to poor treatment outcomes and a heightened risk of adverse toxicity. Although strong associations exist  between its composition and gastrointestinal toxicity, its causal contribution remains unclear. Our inability to move beyond association has limited the development and implementation of microbial-based therapeutics in chemotherapy adjuncts with no clear rationale of how and when to deliver them. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 12, 2021 Category: Cancer & Oncology Authors: Hannah R. Wardill, Stijn A.R. van der Aa, Ana R. da Silva Ferreira, Rick Havinga, Wim J.E. Tissing, Hermie J.M. Harmsen Tags: Original Research Source Type: research

Effectiveness of first-line abiraterone versus enzalutamide among  patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study
Metastatic castration-resistant prostate cancer (mCRPC) disproportionately affects the elderly. There is limited data assessing the efficacy and tolerability of abiraterone acetate (AA) versus enzalutamide in this population. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 12, 2021 Category: Cancer & Oncology Authors: Maryam Soleimani, Kevin Zou, Katherine Sunderland, Werner Struss, Bernie J. Eigl, Lucia Nappi, Christian K. Kollmannsberger, Daygen Finch, Krista Noonan, Joanna Vergidis, Muhammad Zulfiqar, Kim N. Chi, Daniel J. Khalaf Tags: Original Research Source Type: research

Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study
Recent data from the TRIBE2 study have failed to suggest a higher magnitude of benefit from upfront FOLFOXIRI/bevacizumab in patients with BRAF-mutant metastatic colorectal cancer (mCRC) as previously reported in the TRIBE study. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 11, 2021 Category: Cancer & Oncology Authors: Roberto Moretto, Mirella Giordano, Anello M. Poma, Alessandro Passardi, Alessandra Boccaccino, Filippo Pietrantonio, Gianluca Tomasello, Giuseppe Aprile, Sara Lonardi, Veronica Conca, Cristina Granetto, Antonio Frassoldati, Matteo Clavarezza, Alessandro S Tags: Original Research Source Type: research

CD19-specific CAR-T cell therapy for relapsed/refractory non-B-cell acute leukaemia with CD19 antigen expression
CD19-specific chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable efficacy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia (B-ALL) [1,2], and two anti-CD19 CAR-T cell products were approved by U.S. Food and Drug Administration for clinical use in 2017. However, a suitable target antigen for acute myeloid leukaemia (AML) or T-cell acute lymphoblastic leukaemia (T-ALL) has not been identified yet, although some preclinical studies and clinical trials have shown promising effects of CAR-T cell therapy against AML or T-ALL by targeting different antigens such as CD123, CD44v6, Le...
Source: European Journal of Cancer - June 11, 2021 Category: Cancer & Oncology Authors: Shuangyou Liu, Zhichao Yin, Xinjian Yu, Yongqiang Zhao, Jing Pan, Yanzhi Song Tags: Letter to the Editor Source Type: research

Axitinib-related cardiac dysfunction occurring after resumption of treatment
Camastra et  al. [1] reported cardiac magnetic resonance imaging (CMR) of takotsubo cardiomyopathy–like myocardial dysfunction associated with checkpoint-targeted immunotherapy and the usefulness of CMR mapping in diagnosis. Non-invasive imaging modalities circumvent the need for patients with cancer to unde rgo invasive examinations. Accordingly, we used CMR mapping to diagnose an axitinib-related cardiac dysfunction. Axitinib, a tyrosine kinase inhibitor (TKI), is a potent and selective inhibitor of vascular endothelial growth factor receptors. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 11, 2021 Category: Cancer & Oncology Authors: Hidenori Adachi, Madoka Ihara, Yuhei Nojima, Tetsuya Kurimoto, Shinsuke Nanto Tags: Letter to the Editor Source Type: research

High levels of anti-SARS-CoV-2 IgG antibodies in previously infected cancer patients after a single dose of BNT 162b2 vaccine
As patients with cancer constitute a vulnerable population at higher risk of contracting severe COVID-19, they represent a priority group for SARS-CoV-2 vaccination. However, despite favouring these patients theoretically, cancer patients were excluded from major registration trials on SARS-CoV-2 vaccines [1]. Furthermore, two recent reports on the immunogenicity of mRNA vaccines in cancer patients excluded those from the study having previous SARS-CoV-2 exposure [2,3]. We compared IgG antibody levels after one or two doses of BNT162b2 (Pfizer-BioNTech) vaccine in cancer patients with or without prior SARS-CoV-2 infection....
Source: European Journal of Cancer - June 11, 2021 Category: Cancer & Oncology Authors: Dominic Fong, Maximilian J. Mair, Manfred Mitterer Tags: Letter to the Editor Source Type: research

Health-related quality of life in Dutch adult survivors of childhood cancer: A nation-wide cohort study
To investigate the health-related quality of life (HRQOL) of Dutch adult childhood cancer survivors (CCS) and to identify risk factors of impaired HRQOL. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 10, 2021 Category: Cancer & Oncology Authors: L.M.E. van Erp, H. Maurice-Stam, L.C.M. Kremer, W.J.E. Tissing, H.J.H. van der Pal, A.C.H. de Vries, M.M. van den Heuvel-Eibrink, B.A.B. Versluys, J.J. Loonen, D. Bresters, M. Louwerens, M. van der Heiden-van der Loo, M.H. van den Berg, C.M. Ronckers, A.L Tags: Original Research Source Type: research

The incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands: A  population-based study between 1989 and 2018
To describe the incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 9, 2021 Category: Cancer & Oncology Authors: Jan M. van Rees, Marloes A.G. Elferink, Pieter J. Tanis, Johannes H.W. de Wilt, Jacobus W.A. Burger, Cornelis Verhoef Tags: Original Research Source Type: research

Response to letter entitled: Re: Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis
We have read with interest the letter to you from Dr Lockley and colleagues [1] published in response to our manuscript entitled ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis’ that supports surveillance rather than adjuvant chemotherapy in stage I immature teratomas (ITs). This paper was based on the evaluation of the o utcomes of 108 patients with pure ITs, as a result of an international collaboration [2]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 8, 2021 Category: Cancer & Oncology Authors: Alice Bergamini, Naveed Sarwar, Gabriella Ferrandina, Giovanna Scarfone, Dee Short, Xianne Aguiar, Cristina Camnasio, Baljeet Kaur, Philip M. Savage, Gennaro Cormio, Adrian Lim, Sandro Pignata, Giorgia Mangili, Michael J. Seckl Tags: Author ’s reply Source Type: research

Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials
Young women receiving chemotherapy for early breast cancer (EBC) have a high probability for ovarian failure, defined by chemotherapy-induced amenorrhea (CIA) as a surrogate. CIA is insufficiently reliable and reproducible. We analysed chemotherapy-induced ovarian failure (CIOF) by assessing hormone parameters, CIA, and antral follicle count (AFC). (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 8, 2021 Category: Cancer & Oncology Authors: Jenny Furlanetto, Frederik Marm é, Sabine Seiler, Christian Thode, Michael Untch, Sabine Schmatloch, Andreas Schneeweiss, Martina Bassy, Peter A. Fasching, Dominika Strik, Elmar Stickeler, Christian Schem, Thomas Karn, Eva-Maria Grischke, Carsten Denkert Tags: Original Research Source Type: research

Response to the Letter to the Editor by Lockley et al. commenting on ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis’
We have read with interest the letter to you from Dr Lockley and colleagues [1] published in response to our manuscript entitled ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis’ that supports surveillance rather than adjuvant chemotherapy in stage I immature teratomas (ITs). This paper was based on the evaluation of the o utcomes of 108 patients with pure ITs, as a result of an international collaboration [2]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 8, 2021 Category: Cancer & Oncology Authors: Alice Bergamini, Naveed Sarwar, Gabriella Ferrandina, Giovanna Scarfone, Dee Short, Xianne Aguiar, Cristina Camnasio, Baljeet Kaur, Philip M. Savage, Gennaro Cormio, Adrian Lim, Sandro Pignata, Giorgia Mangili, Michael J. Seckl Tags: Author ’s reply Source Type: research

Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
The Italian Network for Tumor Biotherapy (Network Italiano per la Bioterapia dei Tumori  [NIBIT]) Foundation hosted its annual 2020 Think Tank meeting virtually, at which representatives from academic, clinical, industry, philanthropic, and regulatory organisations discussed the role of neoadjuvant immunotherapy for the treatment of cancer. Although the number of neoadjuvant immunothe rapeutic trials is increasing across all malignancies, the Think Tank focused its discussion on the status of neoadjuvant trials in cutaneous melanoma (CM), muscle-invasive urothelial bladder cancer (MIBC), head and neck squamous cell ca...
Source: European Journal of Cancer - June 6, 2021 Category: Cancer & Oncology Authors: Michele Maio, Christian Blank, Andrea Necchi, Anna Maria Di Giacomo, Ramy Ibrahim, Michael Lahn, Bernard A. Fox, R. Bryan Bell, Giampaolo Tortora, Alexander M.M. Eggermont Tags: Current Perspective Source Type: research

Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis
Soft-tissue sarcomas (STSs) are rare malignancies, accounting for approximately 1% of adult cancer. Metastatic disease carries a poor prognosis, and various efforts have been made to improve the prognosis of advanced STS, to date with little success. Immune checkpoint inhibitors (ICPIs) have substantially improved prognosis for many cancer types. Their role in the treatment of STS, however, remains unravelled. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 6, 2021 Category: Cancer & Oncology Authors: Michael Saerens, Nele Brusselaers, Sylvie Rottey, Alexander Decruyenaere, David Creytens, Lore Lapeire Tags: Review Source Type: research

Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
Cutaneous melanoma is notorious for the development of in-transit metastases (ITM). For unknown biological reasons, ITM remain the leading tumour manifestation without progression to distant sites in some patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 5, 2021 Category: Cancer & Oncology Authors: Anne Zaremba, Manuel Philip, Jessica C. Hassel, Valerie Glutsch, Zeno Fiocco, Carmen Loquai, David Rafei-Shamsabadi, Ralf Gutzmer, Jochen Utikal, Sebastian Haferkamp, Lydia Reinhardt, Katharina C. K ähler, Carsten Weishaupt, Alvaro Moreira, Kai-Martin Th Tags: Original Research Source Type: research

Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15
This Phase 2 multicentre trial in localised non-gastric marginal zone lymphoma (MZL) evaluated the effectiveness and safety of radiotherapy and documented markers of autoimmunity and Helicobacter pylori infection. (Source: European Journal of Cancer)
Source: European Journal of Cancer - June 5, 2021 Category: Cancer & Oncology Authors: Michael P. MacManus, Daniel Roos, Peter O'Brien, Anne Capp, Andrew Wirth, Richard Tsang, Mathias Bressel, Stephen Lade, John F. Seymour Tags: Original Research Source Type: research